Cargando…
Recent advances and challenges of bispecific antibodies in solid tumors
Cancer immunotherapy has made remarkable progress in the past decade. Bispecific antibodies (BsAbs) have acquired much attention as the next generation strategy of antibody-target cancer immunotherapy, which overwhelmingly focus on T cell recruitment and dual receptors blockade. So far, BsAb drugs h...
Autores principales: | Wu, Yuze, Yi, Ming, Zhu, Shuangli, Wang, Haiyong, Wu, Kongming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684149/ https://www.ncbi.nlm.nih.gov/pubmed/34922633 http://dx.doi.org/10.1186/s40164-021-00250-1 |
Ejemplares similares
-
Recent advances of bispecific antibodies in solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017) -
Recent advances in targeted strategies for triple-negative breast cancer
por: Zhu, Shuangli, et al.
Publicado: (2023) -
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies
por: Zhu, Shuangli, et al.
Publicado: (2021) -
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
por: Yi, Ming, et al.
Publicado: (2022) -
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
por: Yi, Ming, et al.
Publicado: (2022)